The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Open accessAbstract
Cediranib directly suppresses homology-directed DNA repair in tumor cells and confers synthetic lethal vulnerability to PARP inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The combination of cediranib and olaparib induces lethality by suppressing DNA repair.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,893
XRCC3 promotes homology-directed repair of DNA damage in mammalian cellsPreprint
Pierce, A. J., Johnson, R. D., Thompson, L. H., & Jasin, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2633 · Cited by 1,384
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Veroli, G. Y. D., Fornari, C., Wang, D. Y. Q., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 762
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 720
Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation
Chen, J., Martin, B. L., & Brautigan, D. L. (1992) · Science · doi:10.1126/science.1325671 · Cited by 601
Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 592
Cited by
Sorted by citations
Items 101–158 of 158
Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer
Chen, Y., Tan, L., Gong, J., Huang, M., Yin, J., Zhang, W., Zhou, H., & Liu, Z. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00604-1 · Cited by 10
Pharmacological methods to transcriptionally modulate double-strand break DNA repair
Kaplan, A. R., & Glazer, P. M. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.11.003 · Cited by 9
Self-citation‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancer
Buckley-Benbow, L., Agnarelli, A., & Bellelli, R. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241633 · Cited by 8
Cediranib enhances the transcription of MHC-I by upregulating IRF-1
Zhang, J., Guo, H., Wang, L., Zheng, M., Kong, S., Wu, H., Zhao, L., Zhao, Q., Yang, X., He, Q., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116036 · Cited by 8
Pham, M. M., Hinchcliff, E., Avila, M., & Westin, S. N. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000562 · Cited by 9
Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets
Voutsadakis, I. A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s249540 · Cited by 8
Sy, S. M.-H., Guo, Y., Lan, Y., Ng, H. H. W., & Huen, M. S. Y. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100796 · Cited by 7
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents
Lee, E. K., & Liu, J. F. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_10 · Cited by 6
Li, X., Wu, Y., Zhang, M., Wang, F., Yin, H. X., Zhang, Y., Zhao, S., Ma, J., Lv, M., & Lu, C. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70162 · Cited by 7
Baradács, I., Teutsch, B., Vincze, Á., Hegyi, P., Szabó, B., Nyírády, P., Ács, N., Melczer, Z., Bánhidy, F. G., & Lintner, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051776 · Cited by 6
DNA inhibitors for the treatment of brain tumors
Lisi, L., Chiavari, M., Ciotti, G. M. P., Lacal, P. M., Navarra, P., & Graziani, G. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1729352 · Cited by 6
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?
Marchetti, A., Tassinari, E., Rosellini, M., Rizzo, A., Massari, F., & Mollica, V. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2181783 · Cited by 8
Loss of SIM2s inhibits RAD51 binding and leads to unresolved replication stress
Pearson, S. J., Epps, J. L., Barhoumi, R., Ming-Whitfield, B., Rijnkels, M., & Porter, W. W. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1207-z · Cited by 6
Nanotherapeutics for enhanced treatments for ovarian cancer: a comprehensive minireview
Xu, X., Li, B., Xu, K., & Zhang, T. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2605387 · Cited by 7
Zhao, J., Tang, B., Shen, P., Zeng, H., & Wei, Q. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104698 · Cited by 7
Ramón‐Landreau, M., Sánchez‐Puelles, C., López‐Sánchez, N., Lozano-Ureña, A., Llabrés-Mas, A. M., & Frade, J. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012093 · Cited by 6
Nakai, H., & Matsumura, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2295393 · Cited by 5
Chelariu-Raicu, A., Molin, G. Z. D., & Coleman, R. L. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001789 · Cited by 5
Zaman, N., Kushwah, A. S., Badriprasad, A., & Chakraborty, G. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.004 · Cited by 5
Duffield, J. R., Hou, X., Wilson, B. W., Prasad, A., McKeon-Makki, I. K., Huehls, A. M., Wu, X., Correia, C., Larson, M. C., Couch, F. J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adt8706 · Cited by 5
Jafari, A., Fathi, S., Moosavi, F., & Firuzi, O. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189552 · Cited by 4
Wang, C., Han, X., Kong, S., Zhang, S., Ning, H., & Wu, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117955 · Cited by 7
McFarland, T. R., Kessel, A. C., Swami, U., & Agarwal, N. (2021) · PubMed Central · Cited by 4
Wu, Y., Zhang, X., Li, L., Yang, W., Yan, Z., Gu, C., Zhang, Z., Zhou, J., Liu, L., Ye, M., et al. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s375643 · Cited by 4
LncRNAs in hypoxic microenvironment; insight in their impact in cancer biology
Kuriakose, B. B., Hjazi, A., Saleh, R. O., Bishoyi, A. K., Jyothi, S. R., Almalki, S. G., Sridevi, G., Chaudhary, K., Zwamel, A. H., & Matchonov, O. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01635-9 · Cited by 3
Li, P., Ye, J., Yang, Q., Wang, N., Li, C., Zou, X., Luo, H.-Y., Pan, Y., Jiang, L., Shen, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62295-8 · Cited by 3
Bigdeli, M., Tremblay, E., Provencher, D. M., Mes‐Masson, A., & Rodier, F. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02562-w · Cited by 3
Tashiro, R., Kawazoe, H., Mamishin, K., Seto, K., Udagawa, R., Saito, Y., Hashimoto, H., Shimoi, T., Yonemori, K., Yonemura, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39224-0 · Cited by 3
PARP Inhibitors in Prostate Cancer: A Promise Delivered
Tripathi, A., McFarland, T. R., & Agarwal, N. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.08.006 · Cited by 3
Carucci, M., Clamp, A. R., Zhou, C., Hurt, C. N., Glasspool, R. M., Monaghan, P. J., Thirkettle, S., Wheatley, M., Mahmood, M., Narasimham, M., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13073-0 · Cited by 2
Expression and Prognostic Value of RAD51 in Adenocarcinoma at the Gastroesophageal Junction
Redati, D., Yang, X., Cheng, L., Liu, L., Ge, L., & Wang, H. (2022) · Iranian Journal of Public Health · doi:10.18502/ijph.v51i10.10981 · Cited by 2
Zhang, N., Zheng, H., Gao, Y., Shu, T., Wang, H., & Cai, Y. (2025) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.18179 · Cited by 1
Colón-Ríos, D. A., Dow, J., Krysztofiak, A., Liu, Y., Rogers, F. A., & Glazer, P. M. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf047 · Cited by 1
Self-citationHypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer
Ressel, M. R., Flores, C. E., & Warfel, N. A. (2026) · Cancers · doi:10.3390/cancers18060899 · Cited by 1
Huang, Y., Yang, Y., Zhang, Q., & Wang, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105278 · Cited by 1
Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping review
Iacobelli, V., Camarda, F., Anderson, G., Buttarelli, M., Mastrantoni, L., Ferrara, M. G., Trozzi, R., Duranti, S., Salutari, V., Sabetta, G., et al. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104651 · Cited by 1
Qin, S., An, J., Qiao, W., Zhichao, X., Siyao, T., Seo, G., Zhao, F., & Kim, W. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119670 · Cited by 1
Wang, Y., Cai, Y., & Wang, Q.-M. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/9245663 · Cited by 1
Coleman, R. L., & Ledermann, J. A. (2019) · European Oncology & Haematology · doi:10.17925/eoh.2019.15.1.29 · Cited by 1
The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
Joung, J. Y., & Kim, S. H. (2022) · Journal of Urologic Oncology · doi:10.22465/kjuo.2022.20.1.1 · Cited by 1
Stukan, А. I., Goryainova, А. Y., Викторович, Ш. С., Алексеевна, Г. О., Khachmamuk, Z. K., & Durov, V. V. (2022) · Tumors of female reproductive system · doi:10.17650/1994-4098-2022-18-1-54-65 · Cited by 1
The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer
Christie, E. L., Freimund, A. E., Fereday, S., Alsop, K., Hoang, T., Pishas, K. I., Au‐Yeung, G., Friedlander, M. L., & Bowtell, D. D. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00013-3
Zhang, N., Tian, Y., Zhou, L., Li, M., Song, S., Huan, X., Bao, X.-B., Zhang, A., Miao, Z., & He, J. (2020) · Research Square · doi:10.21203/rs.3.rs-48785/v1
Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids
Volpari, T., Hebner, J., Aiyar, R. S., & Martin, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00080-3
Lee, J., Moore, R. G., Ghamande, S. A., Park, M. S., Diaz, J. P., Chapman, J. A., Kendrick, J. E., Slomovitz, B. M., Tewari, K. S., Lowe, E., et al. (2023) · doi:10.1158/1078-0432.c.6531047
Wang, L., Chen, X., Chen, L., & Li, P. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4971486
Cheng, X., Liu, P., Zhao, Q., Ye, L., Wang, X., Chen, J., Chen, Y., Xu, X., Guo, W., Ni, J., et al. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.114707
Tsang, J. D., & Roberts, C. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.18.677116
Bizzaro, F., Fuso Nerini, I., Taylor, M. A., Anastasia, A., Russo, M., Damia, G. L. M., Guffanti, F., Guana, F., Ostano, P., Minoli, L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16944630
Huang, D., Ke, L., Cui, H., Li, S., & Sun, F. (2024) · Figshare · doi:10.6084/m9.figshare.24995561
Bizzaro, F., Fuso Nerini, I., Taylor, M. A., Anastasia, A., Russo, M., Damia, G. L. M., Guffanti, F., Guana, F., Ostano, P., Minoli, L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16944627
Vicent, S., Welch, C., Novoa, G., Vasquez-Valencia, C., Macaya, I., Jimenez-Alonso, J. J., Subrizio, A., Lagos, A. F., Llorente, S., Jimenez, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9085811/v1
Hou, P., Yang, Z., Liu, Y., Li, H., Yao, Y., Cao, H., Yang, Z.-W., Xiang, K., Wang, J., Chen, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9586117/v1
Self-citationTsang, J. D., & Roberts, C. M. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70298
Li, S., Zhang, J., & Chen, A. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261472998
Ouhajjou, A., Mazouji, O., Nejjari, C., Incitti, R., & Mansour, H. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1891797
Lv, M., Lu, J., Ma, X., Shen, Y., Chen, J., Zheng, H., Fu, S., Xu, J., Wang, M., Xu, Y., et al. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.105611
Metadata
- Authors
- Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., & Glazer, P. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Glazer, Peter M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-05-15
- Volume
- 11
- Issue
- 492
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6626544
- OpenAlex
- W2946425279
- Cited by
- 158
- References
- 34
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 21 · 2023: 23 · 2022: 17 · 2021: 29 · 2020: 31 · 2019: 8
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01ES005775, R35CA197574, R01CA178254, F30CA221065, T32GM007205)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- cediranib, homology-directed repair, BRCA1, BRCA2, RAD51, synthetic lethality, olaparib, DNA repair inhibition, PARP inhibitor combination, tumor xenografts, myelosuppression
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Tumor Hypoxia, Animals, DNA Repair, Female, Humans, Indoles, Mice, Nude, Quinazolines, Down-Regulation, Gene Expression Regulation, Neoplastic, Receptors, Platelet-Derived Growth Factor, BRCA1 Protein, Xenograft Model Antitumor Assays, BRCA2 Protein, Vascular Endothelial Growth Factor Receptor-2, Cell Line, Tumor, E2F4 Transcription Factor, Rad51 Recombinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
